Drug Profile

PN 101

Alternative Names: PN-101; PN-101-01

Latest Information Update: 10 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PAEAN Biotechnology
Class Anti-inflammatories
Mechanism of Action Mitochondria replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Dermatomyositis; Polymyositis

Most Recent Events

07 Feb 2025 The Ministry of Food and Drug Safety grants IND approval for phase II clinical trial of PN 101 in polymyositis and dermatomyositis
07 Feb 2025 Pharmacodynamics data from preclincal trial in Polymyositis and Dermatomyositis released by PAEAN Biotechnology
07 Feb 2025 PAEAN Biotechnology plans a phase II trial for Dermatomyositis and Polymyositis in South Korea (IV), in 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com